The clinical trial of a vaccine that prevents active pulmonary tuberculosis has revealed positive results، according to a recent study، as the Technical Times said.
GSK has announced that M72AS01E candidate vaccine has significantly reduced pulmonary tuberculosis disease in adults after two years of testing. The clinical trial has been conducted in regions where tuberculosis is endemic، including South Africa.
The findings were published in the New England Journal of Medicine this week.
Tuberculosis Vaccine The test involved over 3،000 participants who are HIV-negative adults aged 18 to 50 years old from Kenya، Zambia، and South Africa. They were divided into two groups: one group was to receive two doses of M72AS01E، while the other group was given placebo injections.
After two years، 10 participants from the vaccine group developed active pulmonary tuberculosis disease. To compare، 22 people who received placebo shots developed the disease. The vaccine reports an overall efficacy of 54 percent.
"These initial findings represent a significant innovation in the development of a new and much-needed vaccine and advance the scientific understanding of tuberculosis،" explained Emmanuel Hanon of R&D، Global Vaccines GSK. "This scientific breakthrough — one of the very few in tuberculosis vaccine development for almost 100 years — has been made possible by our strategic partnership with Aeras، in which GSK is providing the innovation expertise and technology platforms، such as the proprietary AS01 adjuvant."